MAIA posts updated investor presentation

MAIA Biotechnology, Inc. filed a current report to note that it has posted an updated presentation about its business on its website.

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. filed a current report to note that it has posted an updated presentation about its business on its website. The slide deck, filed as Exhibit 99.1 and incorporated by reference, is intended to provide summary information alongside the company’s other SEC filings and public announcements. The company states that the presentation speaks only as of the report date and that it does not undertake an obligation to update it. The materials contain forward-looking statements, and investors are cautioned not to place undue reliance on those statements.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did MAIA (MAIA) disclose in this 8-K filing?

MAIA Biotechnology, Inc. disclosed that it posted an updated business presentation on its website, and furnished the slide deck as Exhibit 99.1 to the report.

Where can investors find MAIA Biotechnologys updated presentation?

The company states that the updated presentation about its business is available on its website at www.maiabiotech.com and is also included as Exhibit 99.1 to the report.

Does the MAIA updated presentation form part of the official SEC record?

Yes. MAIA Biotechnology filed the updated presentation as Exhibit 99.1 and incorporated it by reference into the report, making it part of the SEC disclosure record.

How does MAIA describe the information in the new presentation?

MAIA states that the presentation contains summary information about the company and should be considered together with its SEC filings and other public announcements.

Will MAIA Biotechnology update the presentation after this 8-K?

The company notes that while it may update the presentation in the future, it specifically disclaims any obligation to revise or update it after the date of the report.

What caution does MAIA give about forward-looking statements in the presentation?

MAIA explains that the presentation includes forward-looking statements and cautions investors not to place undue reliance on those statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/12/2025 - 04:05 PM Learn about SEC filing dates

false 0001878313 0001878313 2025-09-12 2025-09-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2025

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41455		83-1495913
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

444 West Lake Street, Suite 1700 Chicago, IL		60606
(Address of principal executive offices)		(Zip Code)

(312) 416-8592

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		MAIA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On September 12, 2025, MAIA Biotechnology, Inc. (the “Company”) posted an updated presentation about the Company’s business on its website (www.maiabiotech.com), a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is hereby incorporated by reference.

The information contained in the presentation is summary information that should be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. The presentation speaks as of the date of this Report. While the Company may elect to update the presentation in the future to reflect events and circumstances occurring or existing after the date of this Report, the Company specifically disclaims any obligation to do so.

The presentation contains forward-looking statements, and as a result, investors should not place undue reliance on these forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Presentation Materials
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 12, 2025

	MAIA BIOTECHNOLOGY, INC.
	By:	/s/ Vlad Vitoc
	Name:	Vlad Vitoc
	Title:	Chief Executive Officer

3